NRAS G12V

CI-VAR-00001621Explore in graph →NP_002515.1:p.Gly12ValNM_002524.4:c.35G>TClinVar 40470 CIViC 1175 rs121913237

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm1
NRAS G12V	Cetuximab	Predictive	D	Supports Resistance	—	submitted	EID4465 In an in vitro study, a DiFi colorectal cancer cell line stably expressing NRAS G12V mutation demonstrated resistance to cetuximab treatment compared to DiFi cells expressing wild-type NRAS. Resistanc… (full text at CIViC) PMID 22797062 · Kasper et al., 2013 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
40470	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts	2	Noonan syndrome; RASopathy; Neoplasm; Embryonal rhabdomyosarcoma; Colorectal cancer; Autoimmune lymphoproliferative syndrome type 4; Ovarian Sertoli-Leydig cell tumor	germline/somatic	9	Jun 12, 2024	clinvar